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Unmedicated oral vehicles are used 
to prepare oral liquid medications. 
Compounding of oral liquid formulations 
expands treatment options for patients who 
have difficulty swallowing tablets or cap­
sules, as extemporaneous preparation can 
provide dosage forms that are not commer­
cially available. Specific populations who 
may benefit from the compounding of these 
dosage forms include pediatric patients, 
geriatric patients, and patients with enteral 
feeding tubes. Multiple oral vehicles are 
available, and these products differ in their 
physicochemical and organoleptic proper­
ties. These vehicles can be used to prepare 
a variety of oral liquid dosage forms includ­
ing solutions, suspensions, and emulsions. 
This article provides a review of commer­
cially available oral vehicles as well as a 
discussion of vehicle properties to consider 
when selecting a vehicle for a specific drug, 
route, and patient. This information may 
serve as a reference for compounding phar­
macists as well as for persons involved in 
formulating oral-liquid dosage forms for 
commercial applications.
Discussion
We have reviewed 26 oral liquid 
vehicles, considering various aspects 
such as:
• Appearance
• Osmolality
• pH
• Presence of preservatives and dyes
• Viscosity
• Suspending agent used
• Taste
This information is summarized in Table 
1 as a reference tool for compounding phar­
macists. Additionally, we have examined 
published literature and reference books to 
provide context for this data.
Physicochemical
Properties
Oral dosage forms should be palatable and 
well tolerated, provide accurate and consis-
www.IJPC.com
tent dosing, and maintain physical integrity 
throughout their shelf life.^ Physiochemical 
properties to consider when preparing oral 
liquid formulations include viscosity, sus­
pending agent, pH, and osmolality.
VISCOSITY AND SUSPENDING 
AGENT
Oral liquid dosage forms include solu­
tions, suspensions, and emulsions. In solu­
tions, ingredients are solubilized in the 
solvent. Types of oral solutions include syr­
ups, elixirs, spirits, and tinctures. Multiple 
syrups are commercially available as oral 
liquid vehicles. These do not contain sus­
pending agents, and viscosity is essential 
primarily for pharmaceutical elegance and 
ease ofuse.^
Suspensions are dispersed systems 
which have physical-stability challenges. 
An ideal suspension settles slowly and 
readily re-disperses upon agitation.®
During storage, suspensions may undergo 
sedimentation and aggregation (including 
cake formation) leading to physical insta­
bility and variability in dosing. Inconsistent 
dosing can have severe consequences 
for patients including drug toxicity and, 
conversely, undertreatment. Increased 
viscosity of suspensions can slow the rate 
of particle setting. However, if viscosity 
is too high, the particles may be less read­
ily re-dispersed upon agitation, and the 
product may be difficult to pour and mea­
sure.^'® Suspensions are formulated with 
suspending agents that maintain the physi­
cal stability of the dispersion throughout 
the shelf life. Most of these suspending 
agents are pseudoplastic or shear-thinning 
systems, which leads to lowering of viscos­
ity with respect to increased shear stress 
(i.e., shaking of the bottle or trituration of 
the ingredients to compound the suspen­
sion). Along with the pseudoplastic rheol­
ogy, these systems are also thixotropic, a 
property which allows the system to regain 
its viscosity once the shear stress has been 
removed from the system. The thixotropic 
behavior of such commercial oral vehicles 
enhances the stability and shelf life of the 
compounded oral dispersions.
Like suspensions, emulsions are dis­
persed systems. Specifically, emulsions 
are dispersions of small globules of a sub­
stance in a vehicle in which it is immiscible. 
Because emulsions contain at least two 
phases, often an aqueous and an oleaginous 
phase, they provide a liquid dosage form 
more suitable for drugs that are unstable 
in aqueous formulations. Physical stability 
challenges for emulsions include cream­
ing (weak associations between droplets of 
the internal phase) and cracking (irrevers­
ible coalescence of droplets of the internal 
phase). Viscosity regulators and thickening 
agents may be added to emulsions to slow 
the rate of particle settling and improve the 
stability of the dispersion.® An example of 
an oral liquid vehicle available as an emul­
sification system is Fagron's Unispend 
Anhydrous. This vehicle, available both 
sweetened and unsweetened, is formulated 
with triglycerides and provides an anhy­
drous system which is favorable for water 
unstable additives.^
As evident from Table 1, common sus­
pending agents/viscosity enhancers include 
sodium carboxymethylcellulose, xanthan 
gum, and carrageenan. Each of these agents 
poses their own incompatibility issues that 
a compounding pharmacist must consider 
while using the commercial oral vehicles 
that contain them. A detailed description 
of incompatibility concerns for each of 
these agents is available in the Handbook 
of Pharmaceutical Excipients f This study 
provides a brief overview of some of these 
major incompatibilities with respect to 
each of these agents. Sodium carboxymeth­
ylcellulose solutions are most stable at pH 5 
to 10, however, those solutions can tolerate 
a broader range of pH 2 to 10 for final prepa­
rations. These solutions are also incompat­
ible with quaternary nitrogen-containing 
compounds, iron salts, and metals such as 
aluminum, mercury, and zinc. Similarly, 
due to the anionic chemical structure of 
xanthan gum, it is incompatible with large 
cationic drugs, surfactants, polymers, and 
preservatives. Xanthan gum is also incom­
patible with oxidizing agents, some tablet 
film-coatings, dried aluminum hydroxide 
gel, and some active ingredients such as
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amitriptyline, tamoxifen, and verapamil. 
Lastly, carrageenan-containing solutions 
remain stable at pH 9 and can lead to its 
depolymerization if the pH of the solution 
is rendered acidic. Also, carrageenan may 
interact with cationic active pharmaceuti­
cal ingredients and is generally limited in 
its use in such cases.
A recent study by Visser et al® compares 
the rheological and sedimentation behavior 
of some of the commercially available oral 
vehicles. The study describes the prepara­
tion of an oral suspension of paracetamol 
to evaluate the efficacy of the following
oral vehicles:
• Base for Suspension
• Ora-Blend
• Ora-Blend SF
• Simple Syrup
• Suspendit
• Syr-Spend SF PFI4
The study concludes that SyrSpend SF
PH4 and Suspendit resulted in the best- 
compounded preparations due to their 
pronounced pseudoplastic rheological 
profile. Both the vehicles provided adequate 
sedimentation rates, even pourability, and 
good resuspendability. These results are 
promising. However, the study can further 
be expanded to include other commercially 
available vehicles.
pH
Because many drugs are weak electro­
lytes (weak acids or weak bases), the pH 
of the formulation affects drug ionization, 
solubility, and physicochemical stability. 
Vehicles and formulations may be prepared 
with buffers to prevent sudden changes in 
pH.’' When selecting a vehicle for the oral 
liquid formulation, consideration should be 
given to any data regarding the effect of pH 
on the solubility and stability of the drug 
being prepared in the formulation. Most 
of the oral liquid vehicles described in this 
review have an acidic pH. For drugs that are 
unstable in acidic pH, cdkaline vehicles are 
available. An example of such a product is 
Fagron's SyrSpend SF Alka, which has a pH 
of >7.
OSMOLALITY
Oral vehicles with high osmolality have 
the potential to cause gastrointestinal 
(GI) upset and diarrhea.®*^® Some special 
patient populations are particularly prone 
to osmotic diarrhea. They include pediatric 
patients, geriatric patients, and patients 
with GI comorbidities such as irritable 
bowel syndrome. For instance, hyper­
tonic solutions of >400 mOsm/kg were 
reported to injure GI tracts of neonates.® 
Unfortunately, the osmolality data are not 
available for all vehicles from the manu­
facturers, and estimation is difficult for 
vehicles with proprietary formulas. The fol­
lowing discussion is based on the vehicles 
with reported values (Table 1) and general 
scientific knowledge of oral liquid formula­
tions and excipients.’^^
The osmolality of the normal GI fluids is 
between 100 mOsm/kg to 400 mOsm/kg.’® 
Several sugar-based syrup vehicles contain 
high concentrations of sucrose which result 
in extremely high osmolality. For example, 
the osmolality is 4109 mOsm/kg for Ora- 
Sweet (Perrigo) and 2381 mOsm/kg for Oral 
Syrup (Medisca). The same issue exists 
for some sugar-free vehicles, depending on 
the sweeteners used. Generally, the natural 
polyol sweeteners (e.g., sorbitol) have much 
lower sweetness than the artificial sweeten­
ers (e.g., sucralose) si®!"* and thus require 
much higher concentrations in the formula­
tion. For example, sorbitol is used in a num­
ber of commercial vehicles, and it is only 
about 50% to 70% as sweet as sucrose.^® 
Hence, a vehicle sweetened mainly by sor­
bitol still requires a high concentration of 
sorbitol, which again leads to hyperosmolal­
ity. Furthermore, sorbitol is only partially 
absorbed in the GI tract. The non-absorbed 
sorbitol is fermented by the colonic flora 
with gaseous byproducts, which exacerbate 
the GI disturbances.’® As a safe practice, 
the compounding pharmacist should make 
sure that the sorbitol consumption from 
the prescribed dosage is below 20 g/day 
for adults.® ’® On the other hand, the non- 
sweetened suspension vehicles tend to have 
low osmolality, which are suitable choices 
for patients who cannot tolerate hypertonic 
liquids. Two good vehicle examples are Ora-
Plus from Perrigo and Oral Suspend from 
Medisca at 157 mOsm/kg and 48 mOsm/kg, 
respectively. Finally, one notable product 
worth highlighting is SyrSpend SF from
Fagron. It is the only all-in-one vehicle 
(sweetened, flavored, structured) with a low 
osmolality of <50 mOsm/kg. In addition, 
there are two similar SyrSpend SF powder 
products which are preservative-free but 
require reconstitution before use.
The concern of GI distress is heightened 
when the oral liquids are administered via 
enteral feeding tubes.® ’® Depending on the 
tubing types, the liquid medications are 
delivered directly to various GI regions 
without dilution. As expected, the adverse 
effects are most pronounced when the 
liquids are administered too rapidly into 
the stomach or delivered directly to the 
intestine. Since palatability is not a require­
ment for medications administered via 
enteral feeding tube, it is recommended to 
choose non-sweetened, non-flavored, and 
low-osmolality vehicles. If the viscosity of 
these vehicles presents a challenge for some 
narrow tubes, they should be diluted with 
purified water rather than another vehicle 
with high osmolality.
Preservatives and Dyes
Preservatives are often included in the 
formulations of oral liquid vehicles to pro­
vide microbial stability. Aqueous formula­
tions are prone to microbial growth, and 
preservatives protect against bacterial, 
yeast, and mold infection. In addition to 
protecting the end user from pathogens, 
preservatives also provide a multiple year 
shelf life for products. Parabens are the 
most commonly-used class of preservatives 
which offer protection against a wide range 
of pathogens, even at low concentrations.
Both methylparabens and propylparabens 
have low aqueous solubilities (1 g/400 mL 
of water and 1 g/ 2,500 mL of water, respec­
tively) and are often solubilized with the 
aid of small amounts of a co-solvent such as 
alcohol or propylene glycol. Methylparaben 
is often used as a preferred preservative, 
as it can effectively preserve oral vehicles 
for a broader pH range of 4 to 8. Often, 
methylparaben is paired with propylpara-
.
ii
International Journal of Pharmaceutical Compounding
484 22 No. 6 1 November i December j 2018 www.lJPC.com
TI
B
IE
 1. 
SU
M
M
A
R
Y 
O
F 
VE
H
IC
LE
S 
FO
R
 C
O
M
PO
U
N
D
ED
 O
R
A
L 
LI
Q
U
ID
 M
ED
IC
A
TI
O
N
S.
Basics
a
ei
<
Q, O 
A. 2 
< <
H
CL
>
Eh
<
>
H
CQ
<
■J
<
O
g
wo
ICA
>*Eh
M
a(0
? -a Mw M
A
O o
44: 0 0
44: hO 44
U 44: 1 )
oC
Q <V n
LL DC U-
5
t
•5-1
P = -■=
5
tO
(/) o
O &
^ = CT
sP -P CD
?5 {i>a P
^ S.c
S £^ Si
rtJ sO
■t ”
11 JS —
£ I 
^ .2 ro to
2-I o a 
^ a _g
0)
CD (/)
— ^ O —
^ > Q. "fD ^
Z a
<D m
-Q ^ 2 fo 
2 ^ a
<1> O) O CD
E i a <
£ ^ ^ £ ua> P o p o 75
Z qI Z ex Z U ^ o o
£ o —— 5 »-
!
H
H
w w 
& 2 
CO u
O
•■^ P
<z
j. e - £
= s:
o ^
u = »= = u =P ,2 =0 = is = <z
o = k- = c fc
;= <U CD o> ED CD
International Journal of Pharmaceutical Compounding
Vol. 22 No. 6 I November December 2018 ^85

Basics
H
>>
P
(V
<ua
<i>>.
Q
<
A, U
P 'Z
< <
V■o
5
a;
IEs
<u'
IE
5
Ol■a
5oa
D>c
5o
H
H >
K HH
H Eh 
PJ <! 
Ph >
O) ^ OJ
> > >
>. >.
H
Eh
(»
<
Eh
o>
fO
■a
o>
<c
d
o
u
(/)zo
<
u
Q
O
3
O
<
a
O
Q
Hi
az
3
o
a.
O
u
d:
O
u
XliJ
>
o
>-oc<z
3
iA
<
n4
O S
9
Oc^ S^  .iii
tn
O
u
“ ir H oNN W
A A
H
W a
& z
CA H
5 3 CO CO
a;c
o
Eh 
Q
H
H OA <
w O
CA S
£
fD
V)
u
fD
tn
u
fD
tn
fe tti 05 5.. ni Mp 3 o5 W '■' Q g
5 « o O s
g & o BJ &g H Z P. Z
O (N
“ ffi
H
o
SH>
E 'L
X
Cl
CO
73 tN
X
Q-
LD
O
OCNI
uo
O
ben to achieve a synergistic effect and allow 
the use of low concentrations. Due in part to 
consumer perceptions, many preservative-free 
or paraben-free products are currently being 
marketed. However, available evidence does not 
support a need to avoid parabens, and the safety 
and efficacy of parabens have repeatedly been 
reported. Many prestigious health organiza­
tions worldwide, including the U.S. Food and 
Drug Administration, continue to support the 
use of parabens.^® As evident from Table 1, other 
commonly used preservatives for oral vehicles 
include sodium benzoate and potassium sor- 
bate. Sodium benzoate can be effectively used 
to preserve oral liquids with a pH <5. Several of 
the commercial oral vehicles, including syrups, 
satisfy this qualification and are effectively 
preserved with this water-soluble preserva­
tive. Sodium benzoate’s pH-dependent efficacy 
should be considered with respect to the pH of 
the resulting compounded preparations using 
such oral vehicles. Similarly, potassium sorbate 
can be effectively used as a preservative for oral 
vehicles and formulations with a pH <6. Unlike 
the parabens, potassium sorbate is very soluble 
in aqueous systems (1 g/ 4.5 mL of water) and 
does not require any co-solvents. Additionally, 
Bruns et al also compares the stability of these 
common preservatives and concludes that 
potassium sorbate is the safest alternative for 
pediatric patients with respect to its efficacy 
for compounded oral preparations with a pH of 
3.5 to 5.5.1’'
Dyes provide pharmaceutical elegance to liq­
uid dosage forms. Multiple oral liquid vehicles 
contain dyes, often Red #3 and FD&C #40. For 
patients who are allergic or sensitive to dyes, 
many dye-free vehicles also are available. 
Because neonates have relatively limited meta­
bolic activity, both preservative- and dye-free 
oral liquid vehicles are preferred for this popu­
lation. Compounded oral preprirations for this 
population are generally prepared in limited 
quantities, stored in refrigerators, and consumed 
immediately or within short durations from 
preparation to avoid the use of preservatives.
Organoleptic Properties
Organoleptic properties pertinent to oral 
liquid vehicles include taste, sweetness, and 
appearance. Patient adherence to therapy may
www.IJPC.com International Journal of Pharmaceutical Compounding
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be enhanced when the dosage 
form is palatable and pharma­
ceutically elegant. Some oral 
vehicles are flavored, while oth­
ers are unflavored, allowing the 
compounding pharmacist to 
add flavors that match patient 
preference. Syrups have a high 
degree of sweetness, which 
may be appealing to particu­
lar patient populations such 
as pediatric patients. Some 
vehicles contain sugar-free 
sweeteners (including sugar 
alcohols) with the advantage 
of the lower glycemic load for 
diabetic patients. As discussed 
previously under the topic of 
osmolality, sugar alcohols such 
as sorbitol can cause osmotic 
diarrhea, as can sugars.®
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Ease of Use
For ease of use, 
oral vehicles ide­
ally permit pour­
ing, measuring, 
withdrawal into an 
oral syringe, and 
instillation through 
an enteral feed­
ing tube. Viscosity
should be maintained within a range high 
enough to maintain physical stability but 
low enough to permit these procedures. To 
further facilitate ease of use, the product 
should re-disperse readily upon simple 
agitation.® Prolonged or vigorous agitation 
may be time consuming or complicated for 
providers and patients alike. Additionally, 
patients, pharmacists, and caregivers may 
have different interpretations of the direc­
tions “Shake well before using.”® Dosage 
forms prepared with oral liquid vehicles 
should be able to provide uniform contents 
after simple manual agitation.
Additionally, most of these oral vehicles 
are avculable in conveniently packaged 
one-pint contciiners (473 mL), with a 
24- to 36-month shelf life. This allows 
the pharmacist to easily stock and store 
these buffered, sweetened, flavored, and 
preserved oral vehicles in their inventory. 
Further, current published literature pro­
vides a plethora of information regarding 
the formulation and stability of several 
active pharmaceutical ingredients in these 
commercial vehicles. This strengthens 
the database for utilizing these vehicles to 
provide improved patient care. Due to the 
stability and versatile applications of these 
vehicles for compounded oral-liquid dos­
age forms, several pharmacies have phased 
out from preparing their in-house United 
States Pharmacopeia-compliant oral vehi­
cles. The resulting increase in demand and 
competition by several manufacturers for 
these vehicles thereby feeds the cost-to- 
benefit ratio of purchasing these vehicles.
International Journal of Pharmaceutical Compounding
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Cost Comparison
Standardized, current pricing informa­
tion was not readily available for all the 
products. However, the average wholesale 
price (AWP) reported in Red Book ranged 
from approximately $16 to $63 (USD) per 
473 mL.^® The actual cost of obtaining the 
vehicles can vary significantly from the 
AWP, depending on multiple factors such 
as bulk purchasing discounts and contract 
pricing between the manufacturer and 
buyer. For some of these products, mul­
tiple package sizes are available, which 
could impact pricing.
Limitations
This review is intended to describe com­
mon oral vehicles that may be seen in prac­
tice, and, as such, there may be additional 
oral vehicles on the market which have not 
been included. While multiple flavors and 
package sizes are available for some of the 
products described in this review, these 
parameters were simplified for the sake 
of summarization. In the case of multiple 
available pack^e sizes, a representative 
package size is described in the Tables. The 
representative package size was selected as 
the closest size to 473 mL to facilitate com­
parison between products.
We identified four additional oral liquid 
vehicles, manufactured by Professional 
Compounding Centers of America (PCCA), 
which were not included in Table 1. These 
formulations are proprietary and, as such, 
we were not able to obtain data regarding 
specific ingredients and physicochemical 
properties. These products are PCCA-Plus 
Oral Suspending Vehicle, Syrup Vehicle, 
Sweet-SF Sugar-free Syrup Vehicle, and 
Acacia Syrup. The compounding pharma­
cist may be able to obtain guidance regard­
ing these products from the manufacturer.
An additional limitation is the fact that 
product availability and formulations may 
change over time. This article does not 
replace the responsibility of the compound­
ing pharmacist to check technical data 
sheets and ingredient lists for the oral vehi­
cles that they use to prepare dosage forms.
Conclusion
In conclusion, multiple un-medicated oral 
vehicles are available for use in preparing oral 
formulations. By comparing physicochemical 
and organoleptic properties, the compound­
ing pharmacist can select the oral vehicle best 
suited for the drug, route, and patient.
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